Literature DB >> 27270671

Driving the Way to Tuberculosis Elimination: The Essential Role of Fundamental Research.

Christian Lienhardt1, Alison M Kraigsley2, Christine F Sizemore3.   

Abstract

Tuberculosis has impacted human health for millennia. The World Health Organization estimated that, in 2014, 9.6 million people developed tuberculosis and 1.5 million people died from the disease. In May 2014, the World Health Assembly endorsed the new "End TB Strategy" that presents a pathway to tuberculosis elimination. The strategy outlines 3 areas of emphasis, one of which is intensified research and innovation. In this article we highlight the essential role for fundamental tuberculosis research in the future of tuberculosis diagnostics, treatment, and prevention. To maximize the impact of fundamental research, we must foster collaboration among all stakeholders engaged in tuberculosis research and control to facilitate open dialogue to assure that critical gaps in outcome-oriented science are identified and addressed. We present here a framework for future discussions among scientists, physicians, research and development specialists, and public health managers for the reinforcement of national and international strategies toward tuberculosis elimination.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  biomedical; elimination; global health; research; tuberculosis

Mesh:

Year:  2016        PMID: 27270671      PMCID: PMC5006221          DOI: 10.1093/cid/ciw250

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  34 in total

Review 1.  TB drug development: immunology at the table.

Authors:  Carl Nathan; Clifton E Barry
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

Review 2.  Mycobacterial genes essential for the pathogen's survival in the host.

Authors:  Sabine Ehrt; Kyu Rhee; Dirk Schnappinger
Journal:  Immunol Rev       Date:  2015-03       Impact factor: 12.988

3.  Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis.

Authors:  Ashwin S Dharmadhikari; Randall J Basaraba; Martie L Van Der Walt; Karin Weyer; Matsie Mphahlele; Kobus Venter; Paul A Jensen; Melvin W First; Sydney Parsons; David N McMurray; Ian M Orme; Edward A Nardell
Journal:  Tuberculosis (Edinb)       Date:  2011-04-07       Impact factor: 3.131

4.  Characterization of Mycobacterium tuberculosis complex DNAs from Egyptian mummies by spoligotyping.

Authors:  Albert R Zink; Christophe Sola; Udo Reischl; Waltraud Grabner; Nalin Rastogi; Hans Wolf; Andreas G Nerlich
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

5.  Toward an Evidence-Based Nonclinical Road Map for Evaluating the Efficacy of New Tuberculosis (TB) Drug Regimens: Proceedings of a Critical Path to TB Drug Regimens-National Institute of Allergy and Infectious Diseases In Vivo Pharmacology Workshop for TB Drug Development.

Authors:  Eric Nuermberger; Christine Sizemore; Klaus Romero; Debra Hanna
Journal:  Antimicrob Agents Chemother       Date:  2016-01-11       Impact factor: 5.191

6.  A metabolic biosignature of early response to anti-tuberculosis treatment.

Authors:  Sebabrata Mahapatra; Ann M Hess; John L Johnson; Kathleen D Eisenach; Mary A DeGroote; Phineas Gitta; Moses L Joloba; Gilla Kaplan; Gerhard Walzl; W Henry Boom; John T Belisle
Journal:  BMC Infect Dis       Date:  2014-01-31       Impact factor: 3.090

7.  Whole genome sequencing to complement tuberculosis drug resistance surveys in Uganda.

Authors:  Willy Ssengooba; Conor J Meehan; Deus Lukoye; George William Kasule; Kenneth Musisi; Moses L Joloba; Frank G Cobelens; Bouke C de Jong
Journal:  Infect Genet Evol       Date:  2016-02-23       Impact factor: 3.342

Review 8.  Bridging the gap between evidence and policy for infectious diseases: How models can aid public health decision-making.

Authors:  Gwenan M Knight; Nila J Dharan; Gregory J Fox; Natalie Stennis; Alice Zwerling; Renuka Khurana; David W Dowdy
Journal:  Int J Infect Dis       Date:  2015-11-03       Impact factor: 3.623

9.  A blood RNA signature for tuberculosis disease risk: a prospective cohort study.

Authors:  Daniel E Zak; Adam Penn-Nicholson; Thomas J Scriba; Ethan Thompson; Sara Suliman; Lynn M Amon; Hassan Mahomed; Mzwandile Erasmus; Wendy Whatney; Gregory D Hussey; Deborah Abrahams; Fazlin Kafaar; Tony Hawkridge; Suzanne Verver; E Jane Hughes; Martin Ota; Jayne Sutherland; Rawleigh Howe; Hazel M Dockrell; W Henry Boom; Bonnie Thiel; Tom H M Ottenhoff; Harriet Mayanja-Kizza; Amelia C Crampin; Katrina Downing; Mark Hatherill; Joe Valvo; Smitha Shankar; Shreemanta K Parida; Stefan H E Kaufmann; Gerhard Walzl; Alan Aderem; Willem A Hanekom
Journal:  Lancet       Date:  2016-03-24       Impact factor: 79.321

10.  Eliminating latent tuberculosis.

Authors:  Douglas B Young; Hannah P Gideon; Robert J Wilkinson
Journal:  Trends Microbiol       Date:  2009-04-16       Impact factor: 17.079

View more
  3 in total

Review 1.  The Mycobacterium tuberculosis capsule: a cell structure with key implications in pathogenesis.

Authors:  Rainer Kalscheuer; Ainhoa Palacios; Itxaso Anso; Javier Cifuente; Juan Anguita; William R Jacobs; Marcelo E Guerin; Rafael Prados-Rosales
Journal:  Biochem J       Date:  2019-07-18       Impact factor: 3.857

2.  Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis.

Authors:  Russell R Kempker; M Tobias Heinrichs; Ketino Nikolaishvili; Irina Sabulua; Nino Bablishvili; Shota Gogishvili; Zaza Avaliani; Nestani Tukvadze; Brent Little; Adam Bernheim; Timothy D Read; Jeannette Guarner; Hartmut Derendorf; Charles A Peloquin; Henry M Blumberg; Sergo Vashakidze
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

Review 3.  Advances in clinical trial design: Weaving tomorrow's TB treatments.

Authors:  Christian Lienhardt; Andrew Nunn; Richard Chaisson; Andrew A Vernon; Matteo Zignol; Payam Nahid; Eric Delaporte; Tereza Kasaeva
Journal:  PLoS Med       Date:  2020-02-27       Impact factor: 11.069

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.